

Table 19.31
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2005-2011

Site	All Ages			Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)	
Lymphoid Neoplasm	76,981	69.5 (69.0 , 69.9)		90.2 (89.1 , 91.2)		79.2 (78.7 , 79.7)		58.7 (57.9 , 59.4)	
1 Hodgkin Lymphoma	6,796	86.9 (85.9 , 87.8)		96.9 (95.4 , 97.9)		91.5 (90.5 , 92.4)		54.3 (50.1 , 58.3)	
2 Non-Hodgkin lymphoma	68,074	68.3 (67.8 , 68.8)		88.1 (86.7 , 89.3)		77.3 (76.7 , 77.9)		59.5 (58.7 , 60.2)	
2(a) Non-Hodgkin lymphoma, B-cell	62,931	68.6 (68.1 , 69.1)		88.9 (87.4 , 90.2)		78.1 (77.4 , 78.7)		60.0 (59.2 , 60.8)	
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	3,391	68.8 (67.0 , 70.6)		89.0 (87.3 , 90.4)		38.4 (34.7 , 42.0)		14.5 (9.9 , 19.9)	
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	56,436	68.5 (67.9 , 69.0)		87.5 (83.2 , 90.7)		79.6 (78.9 , 80.2)		60.1 (59.3 , 60.9)	
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	11,934	79.3 (78.0 , 80.5)		- (- , -)		89.1 (87.7 , 90.4)		74.0 (72.3 , 75.7)	
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	10,852	81.6 (80.3 , 82.8)		- (- , -)		91.3 (89.9 , 92.5)		76.5 (74.7 , 78.2)	
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	37	27.2 (11.8 , 45.2)		- (- , -)		- (- , -)		- (- , -)	
2(a) 2.1.3. Mantle-cell lymphoma	1,045	56.7 (52.3 , 60.8)		- (- , -)		69.5 (63.4 , 74.9)		48.5 (42.6 , 54.2)	
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,175	80.0 (75.8 , 83.5)		- (- , -)		87.6 (82.5 , 91.2)		75.7 (69.6 , 80.6)	
2(a) 2.2.1. Lymphoplasmacytic lymphoma	563	73.6 (67.1 , 78.9)		- (- , -)		81.7 (72.6 , 88.0)		69.2 (60.4 , 76.5)	
2(a) 2.2.2. Waldenstrom macroglobulinemia	612	85.8 (80.0 , 90.0)		- (- , -)		91.5 (85.6 , 95.1)		81.7 (72.8 , 87.9)	
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	15,064	61.3 (60.3 , 62.3)		85.4 (79.3 , 89.8)		74.7 (73.4 , 75.9)		51.0 (49.5 , 52.5)	
2(a) 2.3.1. DLBCL, NOS ^c	14,862	61.0 (60.0 , 62.0)		87.2 (81.0 , 91.5)		74.4 (73.1 , 75.6)		51.0 (49.5 , 52.5)	
2(a) 2.3.2. Intravascular large B-cell lymphoma	-	- (- , -)		- (- , -)		- (- , -)		- (- , -)	
2(a) 2.3.3. Primary effusion lymphoma	-	- (- , -)		- (- , -)		- (- , -)		- (- , -)	
2(a) 2.3.4. Mediastinal large B-cell lymphoma	177	85.6 (78.9 , 90.4)		- (- , -)		88.8 (82.0 , 93.1)		- (- , -)	
2(a) 2.4. Burkitt lymphoma/leukemia	594	54.8 (50.2 , 59.1)		88.0 (79.3 , 93.2)		55.6 (49.4 , 61.3)		34.5 (26.9 , 42.2)	
2(a) 2.5. Marginal-zone lymphoma (MZL)	4,881	89.8 (88.1 , 91.2)		- (- , -)		94.0 (92.3 , 95.3)		86.2 (83.3 , 88.6)	
2(a) 2.5.1. Splenic MZL	417	78.9 (72.0 , 84.2)		- (- , -)		86.8 (78.5 , 92.1)		72.3 (61.4 , 80.6)	
2(a) 2.5.2. Extranodal MZL, MALT ^c type	2,983	94.3 (92.1 , 95.9)		- (- , -)		96.5 (94.5 , 97.8)		92.1 (88.0 , 94.8)	
2(a) 2.5.3. Nodal MZL	1,481	83.7 (80.4 , 86.5)		- (- , -)		90.1 (86.2 , 92.9)		79.0 (74.0 , 83.2)	
2(a) 2.6. Follicular lymphoma	9,055	87.4 (86.2 , 88.4)		- (- , -)		92.7 (91.6 , 93.6)		81.1 (78.9 , 83.1)	
2(a) 2.7. Hairy-cell leukemia	283	89.9 (82.2 , 94.4)		- (- , -)		97.7 (93.3 , 99.2)		74.2 (56.0 , 85.7)	
2(a) 2.8. Plasma cell neoplasms	13,443	45.0 (43.9 , 46.2)		- (- , -)		59.8 (58.1 , 61.5)		35.0 (33.4 , 36.5)	
2(a) 2.8.1. Plasmacytoma	706	61.0 (55.6 , 65.9)		- (- , -)		77.0 (70.1 , 82.5)		44.1 (36.4 , 51.6)	
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	12,737	44.2 (43.0 , 45.3)		- (- , -)		58.7 (56.9 , 60.4)		34.5 (33.0 , 36.1)	
2(a) 2.9. Heavy chain disease	-	- (- , -)		- (- , -)		- (- , -)		- (- , -)	
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	3,104	70.7 (68.2 , 72.9)		- (- , -)		79.4 (76.3 , 82.1)		65.9 (62.5 , 69.1)	

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.31 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2005-2011

Site	Count	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)	
2(b) Non-Hodgkin lymphoma, T-cell	4,196	65.3 (63.5 , 67.0)		84.0 (79.2 , 87.8)		71.2 (69.1 , 73.3)		51.6 (48.2 , 55.0)	
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	241	63.3 (56.2 , 69.5)		88.0 (79.5 , 93.2)		48.6 (37.9 , 58.5)		19.4 (5.9 , 38.8)	
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	3,923	65.7 (63.9 , 67.5)		82.4 (76.1 , 87.1)		72.8 (70.5 , 74.9)		52.4 (48.8 , 55.8)	
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,054	90.4 (87.2 , 92.9)		89.8 (59.0 , 97.8)		92.7 (89.4 , 95.1)		85.9 (79.7 , 90.4)	
2(b) 2.1.1. Mycosis fungoides	1,028	91.9 (88.7 , 94.3)		89.8 (59.0 , 97.8)		93.3 (90.0 , 95.6)		88.2 (81.7 , 92.4)	
2(b) 2.1.2. Sezary syndrome	26	28.4 (9.1 , 51.6)		- (- , -)		- (- , -)		- (- , -)	
2(b) 2.2. Peripheral T-cell lymphoma	2,283	58.8 (56.4 , 61.2)		82.9 (72.9 , 89.4)		68.8 (65.7 , 71.6)		43.5 (39.2 , 47.6)	
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	745	38.8 (34.6 , 43.0)		- (- , -)		48.5 (42.5 , 54.3)		28.8 (23.0 , 34.9)	
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	343	48.7 (42.2 , 54.8)		- (- , -)		59.9 (50.7 , 68.0)		39.8 (31.0 , 48.4)	
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	53	70.6 (52.3 , 83.0)		- (- , -)		66.4 (41.6 , 82.6)		- (- , -)	
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	432	62.1 (56.6 , 67.1)		82.2 (68.3 , 90.4)		72.1 (65.8 , 77.5)		30.8 (20.8 , 41.3)	
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	-	- (- , -)		- (- , -)		- (- , -)		- (- , -)	
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	30	19.7 (7.4 , 36.2)		- (- , -)		- (- , -)		- (- , -)	
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	445	83.0 (77.1 , 87.5)		- (- , -)		88.5 (82.3 , 92.6)		74.0 (61.9 , 82.8)	
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	220	90.0 (81.6 , 94.6)		- (- , -)		93.0 (84.8 , 96.8)		80.6 (56.6 , 92.1)	
2(b) 2.3. Adult T-cell leukemia/lymphoma	295	48.8 (41.7 , 55.4)		80.9 (70.8 , 87.9)		32.5 (22.5 , 43.0)		25.6 (13.1 , 40.0)	
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	146	46.7 (36.7 , 56.0)		- (- , -)		47.3 (35.7 , 57.9)		46.3 (27.2 , 63.4)	
2(b) 2.5. T-cell large granular lymphocytic leukemia	69	75.3 (58.1 , 86.3)		- (- , -)		77.7 (51.3 , 90.9)		68.6 (43.4 , 84.3)	
2(b) 2.6. Prolymphocytic leukemia, T-cell	76	12.7 (4.6 , 25.1)		- (- , -)		11.2 (1.1 , 34.7)		12.8 (3.4 , 28.4)	
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	32	33.2 (16.9 , 50.4)		- (- , -)		- (- , -)		- (- , -)	
2(c) Non-Hodgkin lymphoma, unknown lineage	947	59.9 (56.0 , 63.5)		85.8 (80.2 , 89.9)		60.6 (53.7 , 66.8)		45.2 (39.1 , 51.1)	
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	411	64.5 (59.3 , 69.2)		86.7 (81.3 , 90.6)		42.0 (31.0 , 52.6)		20.9 (11.9 , 31.6)	
2(c) 2. Prolymphocytic leukemia, unknown lineage	25	53.4 (27.2 , 73.9)		- (- , -)		- (- , -)		- (- , -)	
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	511	56.5 (50.9 , 61.7)		- (- , -)		71.4 (62.8 , 78.4)		50.2 (43.1 , 56.9)	
2(*) 1. Total precursor lymphoma/leukemia ^d	4,043	68.1 (66.5 , 69.7)		88.7 (87.2 , 90.1)		39.8 (36.5 , 43.0)		16.3 (12.2 , 21.1)	
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	40	45.0 (23.8 , 64.2)		- (- , -)		- (- , -)		- (- , -)	
4 Lymphoid neoplasm, NOS ^c	2,071	49.1 (46.3 , 51.8)		89.6 (71.0 , 96.5)		66.3 (61.8 , 70.3)		39.9 (36.3 , 43.4)	

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.